1
|
Betsou F, Bulla A, Cho SY, Clements J, Chuaqui R, Coppola D, De Souza Y, De Wilde A, Grizzle W, Guadagni F, Gunter E, Heil S, Hodgkinson V, Kessler J, Kiehntopf M, Kim HS, Koppandi I, Shea K, Singh R, Sobel M, Somiari S, Spyropoulos D, Stone M, Tybring G, Valyi-Nagy K, Van den Eynden G, Wadhwa L. Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group. Biopreserv Biobank 2016; 14:398-409. [PMID: 27046294 PMCID: PMC5896556 DOI: 10.1089/bio.2016.0018] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
This technical report presents quality control (QC) assays that can be performed in order to qualify clinical biospecimens that have been biobanked for use in research. Some QC assays are specific to a disease area. Some QC assays are specific to a particular downstream analytical platform. When such a qualification is not possible, QC assays are presented that can be performed to stratify clinical biospecimens according to their biomolecular quality.
Collapse
Affiliation(s)
- Fay Betsou
- Integrated BioBank of Luxemburg (IBBL), Luxembourg, Luxembourg
| | - Alexandre Bulla
- Biotheque-SML, Division of Genetics and Laboratory Medicine (DMGL), University Hospital of Geneva, Geneva, Switzerland
| | - Sang Yun Cho
- National Biobank of Korea, Cheongju, South Korea
| | - Judith Clements
- Australian Prostate Cancer Bioresource/Queensland University of Technology, Brisbane, Australia
| | - Rodrigo Chuaqui
- Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute, Rockville, Maryland
| | - Domenico Coppola
- Moffitt Cancer Center, Department of Anatomic Pathology, University of South Florida, Tampa, Florida
| | - Yvonne De Souza
- University of California, San Francisco, AIDS Specimen Bank, San Francisco, California
| | | | | | | | | | - Stacey Heil
- Coriell Institute for Medical Research, Camden, New Jersey
| | - Verity Hodgkinson
- Cancer Research Division, Cancer Council NSW, Woolloomooloo, Australia
| | | | | | - Hee Sung Kim
- Department of Pathology, Chung-Ang University College of Medicine, Dongjak-gu, South Korea
| | | | | | - Rajeev Singh
- Houston Methodist Research Institute, Biorepository, Houston, Texas
| | - Marc Sobel
- American Society for Investigative Pathology, Bethesda, Maryland
| | - Stella Somiari
- Biobank and Biospecimen Science Research, Windber Research Institute, Windber, Pennsylvania
| | - Demetri Spyropoulos
- Department of Pathology and Laboratory Medicine, Children's Research Institute, Medical University of South Carolina, Charleston, South Carolina
| | - Mars Stone
- Blood Systems Research Institute, San Francisco, California
| | | | - Klara Valyi-Nagy
- University of Illinois Biorepository, Department of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois
| | | | | |
Collapse
|
2
|
Factor VIII and fibrinogen recovery in plasma after Theraflex methylene blue-treatment: effect of plasma source and treatment time. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2014; 12:226-31. [PMID: 24931842 DOI: 10.2450/2014.0176-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Accepted: 09/24/2013] [Indexed: 11/21/2022]
Abstract
BACKGROUND The quality of fresh-frozen plasma is affected by different factors. Factor VIII is sensitive to blood component storage processes and storage as well as pathogen-reduction technologies. The level of fibrinogen in plasma is not affected by the collection processes but it is affected by preparation and pathogen-reduction technologies. MATERIALS AND METHODS The quality of plasma from whole blood and apheresis donations harvested at different times and treated with a pathogen-reduction technique, methylene blue/light, was investigated, considering, in particular, fibrinogen and factor VIII levels and recovery. RESULTS The mean factor VIII level after methylene blue treatment exceeded 0.5 IU/mL in all series. Factor VIII recovery varied between 78% and 89% in different series. The recovery of factor VIII was dependent on plasma source as opposed to treatment time. The interaction between the two factors was statistically significant. Mean levels of fibrinogen after methylene blue/light treatment exceeded 200 mg/dL in all arms. The level of fibrinogen after treatment correlated strongly with the level before treatment. There was a negative correlation between fibrinogen level before treatment and recovery. Pearson's correlation coefficient between factor VIII recovery and fibrinogen recovery was 0.58. DISCUSSION These results show a difference in recovery of factor VIII and fibrinogen correlated with plasma source. The recovery of both factor VIII and fibrinogen was higher in whole blood plasma than in apheresis plasma. Factor VIII and fibrinogen recovery did not appear to be correlated.
Collapse
|
3
|
MacPhee M, Wilmer B, Beall D, Moroff G. Protein composition of clots detected in pooled cryoprecipitate units. Transfusion 2012; 53:651-4. [PMID: 22804740 DOI: 10.1111/j.1537-2995.2012.03778.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND On rare occasions, upon thawing of stored cryoprecipitate components, clots are observed on visual inspection. Although it has been assumed that the clot reflects fibrinogen to fibrin conversion, there are few published studies that document that this assumption is correct. Our studies were conducted to further identify the protein characteristics of the clotted material. STUDY DESIGN AND METHODS Clotted material isolated from four thawed cryoprecipitate pools was examined by solubilization procedures and electrophoresis analysis. RESULTS Solubilization of much of the clotted material in phosphate-buffered saline warmed to 37°C suggested the presence of soluble fibrin. Gel electrophoresis under reducing conditions showed that the most prevalent bands exhibited molecular weights corresponding to the α, β, and γ subunits of fibrinogen with a much lighter band exhibiting the molecular weight of fibrinogen γ-γ dimer, consistent with the presence of partially crosslinked fibrin. The presence of the dimer indicated that the clotted material was caused by the action of thrombin, but also reflected the action of Factor XIIIa. No ongoing clot formation was observed. CONCLUSION Our studies indicate that, on rare occasions, fibrinogen conversion to fibrin is responsible for observable clots in thawed cryoprecipitate pools. These clots are structurally heterogeneous, including both noncrosslinked (soluble) and crosslinked (insoluble) fibrin. This diversity in the fibrin structure may account for some of the diversity in the limited literature regarding their presence in cryoprecipitate pools.
Collapse
Affiliation(s)
- Martin MacPhee
- STB LifeSaving Technologies and the American Red Cross, Holland Laboratory, Rockville, Maryland 20855, USA.
| | | | | | | |
Collapse
|
4
|
A comparative study of the effects of temperature, time and factor VIII assay type on factor VIII activity in cryoprecipitate in Iran. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2011; 9:394-9. [PMID: 21839017 DOI: 10.2450/2011.0064-10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Accepted: 03/23/2011] [Indexed: 11/21/2022]
Abstract
BACKGROUND In Iran, cryoprecipitate is an important plasma product to provide coagulation factors such as factor VIII (FVIII) in patients with factor VIII deficiency. FVIII is one of the labile coagulation factors and as such is also used as a quality marker of fresh-frozen plasma and cryoprecipitate. It is, therefore, important to optimise plasma production in order to prevent a reduction of FVIII activity. In this study we assessed the effect of temperature, time and FVIII assay type on FVIII activity in cryoprecipitate produced in Iran. METHODS Ninety-six whole blood units were kept at two different temperatures (48 units kept at 1-6 °C and 48 kept at 20-24 °C) for periods of 4, 6, 8 or 10 hours before plasma freezing. FVIII activity was then measured by both chromogenic and one-stage clotting assays. RESULTS At both temperatures, FVIII activity in plasma prepared after 8 and 10 hours was lower than that in plasma prepared after 4 and 6 hours. A significant decrease of FVIII activity was not seen in samples kept for 4 and 6 hours. Compared to storage between 1-6 °C, storage at 20-24 °C appears to cause a reduction in FVIII activity. There was a significant difference in apparent FVIII activity measured by the one-stage clot-based and chromogenic assays. CONCLUSION In Iran, to improve cryoprecipitate quality, freezing should begin within 6 hours after donation and whole blood should be kept at 1-6 °C until the plasma can be frozen. In this study although a good correlation was seen between the results of the one-stage clot-based and chromogenic assays for measuring FVIII activity in cryoprecipitate, the absolute values were significantly different.
Collapse
|
7
|
Abstract
Many plasmapheresis techniques cause greater activation of platelets, complement and coagulation than does simple whole blood collection. Activation of the coagulation cascade has been particularly evident in tests for potential thrombogenicity in prothrombin complex concentrates made from apheresed plasma. Attempts to improve the factor VIII content and fractionation yield of source plasma have centred on rapid freezing, increased concentration of anticoagulants and the exploitation of anticoagulants optimal for the preservation of coagulant, rather than cellular, activities. The cumulative advantage is of the order of 10% over recovered plasma. There are potential pitfalls in applying low-citrate anticoagulation strategies to plasmapheresis. Recalcification of citrated plasma, under cover of an optimal concentration of heparin, might be explored more vigorously.
Collapse
|
8
|
Vaara I, Jonsson M. Preservation of factor VIII activity in plasma by different freezing techniques, as determined with a chromogenic microtray assay. Scand J Clin Lab Invest 1989; 49:161-4. [PMID: 2520368 DOI: 10.3109/00365518909105416] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The preservation of factor VIII activity in frozen plasma was studied using three different freezing techniques. Two were conventional methods, i.e. ethanol bath at -40 degrees C, and deep-frozen at -80 degrees C, and the third was a novel air-based -40 degrees C freezer with metal compartments and snugly fitting flat 750 ml plasma containers. No statistically significant difference in preservation of factor VIII was observed, irrespective of freezing technique, as determined with a chromogenic substrate assay.
Collapse
Affiliation(s)
- I Vaara
- Department of Clinical Chemistry, Central Hospital, Växjö, Sweden
| | | |
Collapse
|
9
|
Janvier G, Winnock S, Dugrais G, Vallet A, Piquet Y, Tajan I, Tajan Y, Erny P, Vezon G. [Effect of shaking the bag receiving the blood on blood cell elements and various plasma coagulation factors]. ANNALES FRANCAISES D'ANESTHESIE ET DE REANIMATION 1989; 8:231-3. [PMID: 2782685 DOI: 10.1016/s0750-7658(89)80108-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- G Janvier
- Département d'Anesthésie-Réanimation I, Hôpital Pellegrin-Tripode, Bordeaux
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Carlebjörk G, Oswaldsson U, Rosén S. A simple and accurate microplate assay for the determination of factor VIII activity. Thromb Res 1987; 47:5-14. [PMID: 3116712 DOI: 10.1016/0049-3848(87)90235-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Based on the CoatestR Factor VIII kit, a simple and accurate microtiter plate assay has been developed. The method has been simplified through the combination of the bovine factors IXa + X, phospholipid and calcium chloride into one reagent. A further improvement was obtained by generating F Xa to a stable plateau level, thus minimizing influences from variations in time and temperature. The substrate hydrolysis was terminated with 1 M citrate buffer, pH 3.0, which reduced the environmental effects as compared to acetic acid. Overall a fourfold reduction in reagent consumption was achieved. A high correlation with clotting assays was obtained with various types of factor VIII concentrates as well as with plasma samples from blood donors and hemophilia A patients (r greater than 0.85). The accuracy was proven over the whole investigated range of factor VIII activities. Finally, the described microplate assay allows a high turnover of samples in a short period of time, still maintaining a coefficient of variation below 5%.
Collapse
Affiliation(s)
- G Carlebjörk
- Department of Clin. Chem. and Blood Coagulation, Karolinska Institutet, Stockholm, Sweden
| | | | | |
Collapse
|
13
|
Skjønsberg OH, Kierulf P, Gravem K, Fagerhol MK, Godal HC. Contaminating fibrin in CPD-blood: solubility in plasma and distribution in blood components following separation. Thromb Res 1986; 41:1-8. [PMID: 3961724 DOI: 10.1016/0049-3848(86)90274-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
In order to estimate the solubility of contaminating fibrin in CPD-blood, thrombin induced fibrin polymerzation in CPD-plasma was examined by light scattering and fibrinopeptide A (FPA) determinations. In addition, I125 fibrin monomer enriched CPD-blood was used to investigate fibrin monomer retention in blood bags and transfusion filters (170 microns) and fibrin distribution in blood components derived from CPD-blood. Initial fibrin polymerization in CPD-blood occurred after conversion of 15 per cent of the fibrinogen to fibrin, implying that substantial amounts of fibrin may be kept solubilized in CPD-blood bags. Only minor amounts of I125 fibrin monomers were retained in blood bags (2.4 per cent) and in transfusion filters (2.9 per cent) after sham transfusions. After separating I125-fibrin monomer enriched CPD-blood into its constituent components, the major part of fibrin (75.0 per cent) could be traced in the cryoprecipitate.
Collapse
|